Yesterday, Feb. 17, 2016, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.30 to $7,252,323.17.

Highlighted Stocks Traded by Insiders:

Walker & Dunlop (WD) - FREE Research Report

Schmaltz Dana L, who is Director at Walker & Dunlop, bought 1,500 shares at $20.20 on Feb. 17, 2016. Following this transaction, the Director owned 35,339 shares meaning that the stake was boosted by 4.43% with the 1,500-share transaction.

The shares most recently traded at $22.42, up $2.22, or 9.91% since the insider transaction. Historical insider transactions for Walker & Dunlop go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 58,897

The average volume for Walker & Dunlop has been 244,300 shares per day over the past 30 days. Walker & Dunlop has a market cap of $656.3 million and is part of the financial sector and real estate industry. Shares are down 24.57% year-to-date as of the close of trading on Wednesday.

Walker & Dunlop, Inc., through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products for owners and developers of real estate in the United States. The company has a P/E ratio of 8.1. Currently, there are 2 analysts who rate Walker & Dunlop a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WD - FREE

TheStreet Quant Ratings rates Walker & Dunlop as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, solid stock price performance and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Walker & Dunlop Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

HCP (HCP) - FREE Research Report

Stasinos John D., who is Executive Vice President at HCP, bought 400 shares at $26.24 on Feb. 17, 2016. Following this transaction, the Executive Vice President owned 23,539 shares meaning that the stake was boosted by 1.73% with the 400-share transaction.

The shares most recently traded at $27.98, up $1.74, or 6.22% since the insider transaction. Historical insider transactions for HCP go as follows:

  • 4-Week # shares bought: 35,000
  • 4-Week # shares sold: 32,875
  • 12-Week # shares bought: 35,000
  • 12-Week # shares sold: 32,875
  • 24-Week # shares bought: 50,900
  • 24-Week # shares sold: 32,875

The average volume for HCP has been 4.6 million shares per day over the past 30 days. HCP has a market cap of $12.5 billion and is part of the financial sector and real estate industry. Shares are down 28.43% year-to-date as of the close of trading on Wednesday.

HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. The stock currently has a dividend yield of 8.54%. Currently, there are 2 analysts who rate HCP a buy, 4 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCP - FREE

TheStreet Quant Ratings rates HCP as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full HCP Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NxStage Medical (NXTM) - FREE Research Report

Lewis Earl R, who is Director at NxStage Medical, bought 21,000 shares at $14.63 on Feb. 17, 2016. Following this transaction, the Director owned 88,145 shares meaning that the stake was boosted by 31.28% with the 21,000-share transaction.

The shares most recently traded at $14.45, down $0.18, or 1.22% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 3,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 10,380
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 37,113

The average volume for NxStage Medical has been 576,800 shares per day over the past 30 days. NxStage Medical has a market cap of $908.6 million and is part of the health care sector and health services industry. Shares are down 35.28% year-to-date as of the close of trading on Wednesday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 5 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings rates NxStage Medical as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full NxStage Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.